NEW: No-Cost StreetSmart Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

Sector Expert: Juan Sanchez

Ladenburg Thalmann

Dr. Juan F. Sanchez is a vice president at Ladenburg Thalmann & Co. Inc, Research Division. He covers biotechnology and nanotechnology sectors with a focus on central nervous system therapeutics. Dr. Sanchez's previous experience includes oncology marketing at Bristol Myers Squibb and post-genomic strategy planning at the Office of the Vice Provost, Columbia University. He has five years of experience in clinical medical practice. Dr. Sanchez received a Master in International Affairs from Columbia University, a Master of Business Administration from University of Los Andes and a Medical Doctor degree from Javeriana University.



Recent Interviews

Platform Technologies Promise Big Payoffs: Juan Sanchez (2/10/12)

Platform technologies promise big payoffs because they offer the prospect of nearly unlimited assets that might be developed to combat disease, but they make investors very nervous because of their propensity to burn cash in a hurry. In this exclusive interview with The Life Sciences Report, Ladenburg Thalmann & Co. Vice President and Senior Analyst Juan Sanchez makes his case for a few companies that could produce numerous products from their technology-rich pipelines.

Recent Quotes

"We believe the ADX71149 program could be potentially transformative for ADXN."

— Juan Sanchez, Ladenburg Thalmann (2/8/13)
more >

"ADXN has two assets addressing real medical needs in midstage clinical development."

— Juan Sanchez, Ladenburg Thalmann (11/5/12)
more >

"We reiterate our Buy rating on ADXN."

— Juan Sanchez, Ladenburg Thalmann (8/29/12)
more >

"We reiterate our Buy rating on ADXN."

— Juan Sanchez, Ladenburg Thalmann (8/22/12)
more >

"Data show ADXN's dipraglurant is safe and active (in treating LID)."

— Juan Sanchez, Ladenburg Thalmann (6/21/12)
more >

"Positive data from a phase 2 study of ADX71149 could be transformative for ADXN."

— Juan Sanchez, Ladenburg Thalmann (6/5/12)
more >

"New findings highlight dipraglurant's potential positioning; ADXN is a Buy."

— Juan Sanchez, Ladenburg Thalmann (12/6/11)
more >

"ADXN is advancing its internal pipeline, generating important partnerships."

— Juan Sanchez, Ladenburg Thalmann (8/16/11)
more >



Due to permission requirements, not all quotes are shown.